TY - JOUR T1 - Prognostic value of promoter hypermethylation of tumor suppressor genes in malignant pleural fluid JF - European Respiratory Journal JO - Eur Respir J VL - 38 IS - Suppl 55 SP - p3544 AU - Maribel Botana-Rial AU - Loreta de Chiara AU - Virginia Leiro-Fernández AU - Diana Valverde AU - Cristina Represas- Represas AU - Ana Isabel González-Silva AU - Alberto Fernández-Villar Y1 - 2011/09/01 UR - http://erj.ersjournals.com/content/38/Suppl_55/p3544.abstract N2 - Background: To determine the prognostic value of promoter hypermethylation of p16/INK4a, MGMT, BRCA1 and RAR β genes in pleural fluid (PF) and other clinicopathological parameters in malignant pleural effusion (MPE).Methods: We evaluated 49 patients.We recorded clinical characteristics, characteristics of the PF, the detection of promotor hypermethylation of the tumor suppressor genes in PF by methylation-specific polymerase chain reaction.Results: We inclued 37 (75.5%) lung cancer patients and 12 (24.6%) with others epithelial neoplasias.The median time of global survival was of 255.5 (IC 95%:56-488.5) days.Parameters associated with a minor survival were: the presence of others metastasis (p=0.003); no chemotherapy treatment (p=0.001); pH<7.28 (p=0.004); glucose<60 (p=0.002) and the absence of some methylated gene (p=0.003).After the multivariate analysis, chemotherapy treated have a significantly reduced risk of death (OR=0.05;p = 0.001).Patients with metastasis (OR = 5.1;p=0,001) and patients with pH <7.28 (OR=3.2;p=0.03) have more risk of death.Chemotherapy treatment received (OR=0.1;p=0.001) and the presence of methylated genes (OR=0.2;p=0.02) were factors associated with major survival in patients with lung adenocarcinoma diagnosis.Conclusions: In patients with lung adenocarcinoma, the presence of promotor hypermethilation of genes and history of chemotherapy treatment were significantly associated with major survival.Tumor extension, not having received chemotherapy and the caracteristics of the PF were factors related to the risk of death in all MPE patients analyzed.FIS-FEDER PI081100, Conselleria de Sanidade PS08/18, SOGAPAR 2007, Intensification activity from FIS ER -